Journal Menu► ▼ Journal Menu
Journal Browser► ▼ Journal Browser
Special Issue "Drug Resistance in Hematologic Malignancies"
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".
Deadline for manuscript submissions: 31 December 2019.
Prof. Dr. Jerome Tamburini-Bonnefoy
Cochin Hospital, Assistance Publique–Hôpitaux de Paris, Paris, France
Interests: Acute Myeloid Leukemia; signaling pathways; Drug resistance
Resistance to therapies is a hallmark and major drawback of all cancers. Hematological malignancies define a highly heterogeneous set of blood, bone marrow, and organ-associated diseases with highly variable prognosis that constantly relapse upon treatment. Although some of these diseases, such as Chronic Myelogenous Leukemia (CML), are now almost always curable thanks to targeted therapies, many others remain a major public health concern. Nevertheless, considerable progresses have been made in the management of patients suffering from hematological malignancies in these past ten years, and patients now beneficiate from a plethora of treatments, from conventional to targeted and immunotherapies. Whatever the kind of treatment, malignant hematopoietic cells consistently develop cellular strategies to adapt and survive to therapeutic drugs. Such an adaptation may involve different molecular and cellular mechanisms, including the acquisition of mutations. In addition, the modulation of the signaling pathways involved in apoptosis, autophagy, proliferation, proteostasis, metabolism, epigenetic modifications, and the modulation of oncogenes or tumor suppressors represent additional processes which may lead to therapy-induced resistance. Other potential mechanisms of resistance arise from the tumor stromal niche, for instance, through cytokines and growth factors production or exosome secretion. This Special Issue of IJMS will encompass the ensemble of the resistance processes set up in the course of hematological malignancies treatment and the mechanisms by which alterations of these pathways can be therapeutically exploited to improve therapies.
Dr. Patrick Auberger
Prof. Dr. Jerome Tamburini-Bonnefoy
Dr. Alexandre Puissant
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Blood and Bone Marrow Cancers
- Resistance to Therapy
- Conventional, Targeted and Immunotherapies
- Cell Signalling
- Cytokines/Growth Factors
- Oncogenes/Tumor Suppressors
- Organelle biogenesis
The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.
- Mechanisms of Resistance to Ibrutinib in Lymphoid Malignancies
- Mechanisms of Evasion to TKI in CML
- Mechanism of Resistance in T-ALL and ETP- ALL
- Resistance and Escape to Anti-CD19 Immunotherapies in ALL
- HMA Resistance in MDS and AML
- Resistance to ESA and EMA in MDS
- Acadesine Circumvents Azacitidine Resistance in Myelodysplastic Syndrome and Acute Myeloid Leukemia
- Mechanisms of Drug Resistance in FLT3 Mutant AML
- Transcriptional and Epigenetic Cell States Mediating Therapeutic Resistance and Minimal Residual Disease in B Cell Malignancies
- Role of Autophagy in Drug Resistance of Acute Promyelocytic Leukemia
- ITK in AML Treatment